SCHEMBL5952448

SCHEMBL5952448

CCOc1ccc(C(N)=O)c(N)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.56
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
PKM P14618 1/20 0.46
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PLAU P00749 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
F2 P00734 1/20 0.45
F10 P00742 1/20 0.45
PLAT P00750 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11833005 0.86 KDM4E (0.53) PARP10KDM4EALDH1A1LMNAMAPT
SCHEMBL18823988 0.86 KDM4E (0.57) PARP10KDM4EALDH1A1LMNAMAPT
SCHEMBL27249089 0.86 PARP10 (0.56) PARP10KDM4EALDH1A1LMNAMAPT
SCHEMBL6838380 0.84 KDM4E (0.68) PARP10KDM4EALDH1A1MEN1KMT2A
SCHEMBL10362606 0.83 ALDH1A1 (0.58) PARP10KDM4EALDH1A1LMNAMAPT
SCHEMBL22749335 0.83 ALDH1A1 (0.58) PARP10KDM4EALDH1A1LMNAMAPT
SCHEMBL10407907 0.83 PLAU (0.58) PARP10KDM4EALDH1A1MAPTMEN1
SCHEMBL148855 0.80 ALDH1A1 (0.53) PARP10KDM4EALDH1A1LMNAMAPT
SCHEMBL4685251 0.80 PARP10 (0.63) PARP10KDM4EALDH1A1LMNAMAPT
Hydrochloric Acid SCHEMBL30779145 0.80 PARP10 (0.59) PARP10KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 PARP10 2144/4885KDM4E 522/4885ALDH1A1 1389/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A PARP10 2378/4885KDM4E 645/4885ALDH1A1 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.